BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price
BBOTStock
$9.37+3.39%52W
Market Cap$751.23M
P/E86.81x
PEG Ratio—
Div yield—
Beta0.38
BBOT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-25.91%
Price vs S&P 500 (4W)3.35%
VGM Score43.65
P/E Ratio (Annual)86.81x
BBOT Earnings Surprise History
Q2 25-50.36est. —
Q3 25-1.03est. -0.34
Q4 25-0.49est. -0.66
Q2 26-0.71est. -0.54
BBOT Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.31
4.31
4.29
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock | — | D | C | $9.37 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About BridgeBio Oncology Therapeutics, Inc. Common Stock
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing cancer therapies that target RAS and PI3Ka mutations, two of the most frequently mutated oncogenic drivers. The company aims to address unmet needs in oncology by creating targeted treatments for patients with these genetically-driven cancers.